These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32877661)

  • 1. Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
    Freriksen JJM; Meijerhof M; van Drongelen J; Drenth JPH; Burger DM; Russel FGM; Colbers A; Greupink R
    Am J Obstet Gynecol; 2020 Dec; 223(6):941-943. PubMed ID: 32877661
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
    Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection.
    Al-Nahari MM; Abbassi MM; Ebeid FS; Hassany M; El-Sayed MH; Farid SF
    Antivir Ther; 2020; 25(2):101-110. PubMed ID: 32367815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients.
    Schrezenmeier E; Hoffmann F; Jaeger C; Schrezenmeier J; Lisec J; Glander P; Algharably E; Kreutz R; Budde K; Duerr M; Halleck F
    Ther Drug Monit; 2019 Feb; 41(1):53-58. PubMed ID: 30422962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective and Safe Daclatasvir Drug Exposures Predicted in Children Using Adult Formulations.
    Cressey TR; Abbassi M; Lallemant M; Indolfi G; Al-Nahari M; Farid S; Penazzato M; Easterbrook P; El-Sayed MH
    Pediatr Infect Dis J; 2021 Dec; 40(12):1081-1086. PubMed ID: 34321444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral treatment failure in genotype 2 hepatitis C chronic infection.
    Ridruejo E; Piñero F; Mendizabal M; Silva M;
    J Viral Hepat; 2021 Feb; 28(2):446-447. PubMed ID: 33147362
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment.
    Mogalian E; Brainard DM; Osinusi A; Moorehead L; Murray B; Ling KHJ; Perry R; Curtis C; Lawitz E; Lasseter K; Marbury T; Mathias A
    Clin Pharmacokinet; 2018 Nov; 57(11):1449-1457. PubMed ID: 29520729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synchronous spectrofluorimetry and chemometric modeling: A synergistic approach for analyzing simeprevir and daclatasvir, with application to pharmacokinetics evaluation.
    Serag A; Alnemari RM; Abduljabbar MH; Alosaimi ME; Almalki AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jul; 315():124245. PubMed ID: 38581722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
    Chan HT; Chao CM; Lai CC
    J Infect; 2021 Apr; 82(4):e34-e35. PubMed ID: 33373651
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic Profile of a Generic Formulation of Sofosbuvir and Its Metabolite GS-331007 in Healthy Chinese Subjects.
    Shen Z; Zhu X; Zhang H; Chen H; Niu J; Chen G; Li X; Ding Y
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):1073-1080. PubMed ID: 30900816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of isotopically labeled daclatasvir for use in human clinical studies.
    Easter JA; Burrell RC; Bonacorsi SJ
    J Labelled Comp Radiopharm; 2016 Apr; 59(4):164-70. PubMed ID: 26968868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    Lawitz E; Poordad F; Gutierrez JA; Kakuda TN; Picchio G; Beets G; Vandevoorde A; Van Remoortere P; Jacquemyn B; Luo D; Ouwerkerk-Mahadevan S; Vijgen L; Van Eygen V; Beumont M
    J Viral Hepat; 2017 Apr; 24(4):287-294. PubMed ID: 27878906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients.
    Notari S; Tempestilli M; Fabbri G; Libertone R; Antinori A; Ammassari A; Agrati C
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():183-190. PubMed ID: 29276983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of hepatitis C virus infection with sofosbuvir and daclatasvir 90 mg in a patient with severe epilepsy on oxcarbazepine.
    Smolders EJ; de Kanter CT; van 't Veer N; D'avolio A; Di Perri G; Burger DM; van Wijngaarden P
    Int J Antimicrob Agents; 2016 Sep; 48(3):347-8. PubMed ID: 27516229
    [No Abstract]   [Full Text] [Related]  

  • 15. Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population.
    Huang H; Wang J; Li Q; Duan J; Yao Q; Zheng Q; Wang J; Wu D; Zhou Q; Tian Y; Zhang J
    J Matern Fetal Neonatal Med; 2017 Jun; 30(11):1288-1292. PubMed ID: 27426925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interactions in anti-HCV therapy: a comparison among options available in Italy.
    Di Perri G; Cariti G
    Infez Med; 2019 Sep; 27(3):239-250. PubMed ID: 31545767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.
    Chahine EB; Sucher AJ; Hemstreet BA
    Ann Pharmacother; 2017 Jan; 51(1):44-53. PubMed ID: 27609942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model.
    Berveiller P; Mir O; Vinot C; Bonati C; Duchene P; Giraud C; Gil S; Treluyer JM
    Am J Obstet Gynecol; 2012 Jan; 206(1):92.e1-6. PubMed ID: 21958869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying different spectroscopic techniques for the selective determination of daclatasvir using merbromin as a probe: Applications on pharmaceutical analysis.
    Almahri A; Abdel-Lateef MA
    Luminescence; 2021 Sep; 36(6):1544-1552. PubMed ID: 34080773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
    Summers BB
    Drugs Today (Barc); 2018 Apr; 54(4):255-268. PubMed ID: 29869647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.